Glioma
|
0.900 |
Biomarker
|
disease |
BEFREE |
This result suggests that EX527 induced cell apoptosis by activating p53 in glioma.
|
31490284 |
2020 |
Glioma
|
0.900 |
Biomarker
|
disease |
BEFREE |
Therefore, this study was conducted to explore the effects and mechanism of RAD18 in the radiation resistance of glioma and study P53 role in this process.
|
30798132 |
2019 |
Glioma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Translation of these findings to patients with IDH1<sup>132H</sup> glioma harboring TP53 and ATRX loss could improve the therapeutic efficacy of radiotherapy and, consequently, patient survival.
|
30760578 |
2019 |
Glioma
|
0.900 |
Biomarker
|
disease |
BEFREE |
Overexpression of YB-1 or MDM2 renders a drug resistance feature in glioma cell exposed to temozolomide (TMZ), by directly targeting p53.
|
30679904 |
2019 |
Glioma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest that a ploidy threshold is the main determinant of Aurora kinases sensitivity in TP53 mutant glioma stem cells.
|
31531022 |
2019 |
Glioma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
However, TLX overexpression in NSCs induces long-term NSC expansion and further leads to glioma initiation in mouse when combined with p53 mutations.
|
27881004 |
2019 |
Glioma
|
0.900 |
Biomarker
|
disease |
BEFREE |
LncRNA SAMD12-AS1 down-regulates P53 to promote malignant progression of glioma.
|
31646576 |
2019 |
Glioma
|
0.900 |
GeneticVariation
|
disease |
GWASCAT |
Sex-specific glioma genome-wide association study identifies new risk locus at 3p21.31 in females, and finds sex-differences in risk at 8q24.21.
|
29743610 |
2018 |
Glioma
|
0.900 |
Biomarker
|
disease |
BEFREE |
Glioma targeting peptide in combination with the P53 C terminus inhibits glioma cell proliferation in vitro.
|
28879517 |
2018 |
Glioma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Radiomics Strategy for Molecular Subtype Stratification of Lower-Grade Glioma: Detecting IDH and TP53 Mutations Based on Multimodal MRI.
|
29394005 |
2018 |
Glioma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
These findings suggest that the pri-miR-34b/c rs4938723CC and TP53 Arg72-Pro polymorphisms may be associated with the risk of glioma.
|
30319976 |
2018 |
Glioma
|
0.900 |
Biomarker
|
disease |
BEFREE |
In conclusion, this bioinformatics analysis indicated that DEGs and core genes, such as TP53, might influence the development of glioma, especially in tumor proliferation, which were expected to be promising biomarkers for diagnosis and treatment of glioma.
|
30405856 |
2018 |
Glioma
|
0.900 |
Biomarker
|
disease |
BEFREE |
The screened DEG p53 gene is likely to be critical for glioma development, including via the Wnt and p53 signaling pathways.
|
29435008 |
2018 |
Glioma
|
0.900 |
AlteredExpression
|
disease |
BEFREE |
The retention of mutant p53 transcriptional activity prognosticates superior survival for men with glioma and gastric adenocarcinoma harboring sporadic TP53 mutations.
|
30089713 |
2018 |
Glioma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
This IPD meta-analysis suggests that TP53 alteration is a valuable predictor for the prognosis of patients with H3K27M mutated gliomas.
|
29651718 |
2018 |
Glioma
|
0.900 |
Biomarker
|
disease |
BEFREE |
The classification of gliomas has been restructured with the discovery of isocitrate dehydrogenase (IDH) 1/2 mutations in the vast majority of lower grade infiltrating gliomas and secondary glioblastomas (GBM), with IDH-mutant astrocytomas further characterized by TP53 and ATRX mutations.
|
29521646 |
2018 |
Glioma
|
0.900 |
AlteredExpression
|
disease |
BEFREE |
Human corticotrophin releasing factor inhibits cell proliferation and promotes apoptosis through upregulation of tumor protein p53 in human glioma.
|
29805572 |
2018 |
Glioma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
The expression score (P<0.05) and positive expression rate (χ2=31.27, P<0.05) of mutant p53 in glioma was significantly higher compared with those in normal brain tissue.
|
29620180 |
2018 |
Glioma
|
0.900 |
Biomarker
|
disease |
BEFREE |
It was revealed that rNDV-p53 inhibits glioma cell growth and aggressiveness <i>in vitro</i> and <i>in vivo</i> compared with rNDV and p53 alone.
|
29731836 |
2018 |
Glioma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Fifty-two percent of patients diagnosed with glioma/glioblastoma with a positive TP53 mutation had at least one concurrent mutation in a known pathogenic gene of which 9% were CDKN2A, 41% were IDH1, and 11% were PIK3CA.
|
29454261 |
2018 |
Glioma
|
0.900 |
Biomarker
|
disease |
BEFREE |
The objective of this study was to assess the influence of graphite nanoparticles (NG) and graphene oxide nanoplatelets (nGO) on the angiogenic potential of glioma cell lines with different p53 statuses.
|
30283098 |
2018 |
Glioma
|
0.900 |
Biomarker
|
disease |
BEFREE |
We examined 12 SNPs in TP53 from peripheral blood and neoplastic tissue of patients with a diagnosis of glioma who underwent surgery from 2012 to 2015.
|
29308633 |
2018 |
Glioma
|
0.900 |
Biomarker
|
disease |
BEFREE |
Transcriptional Repression of p53 by PAX3 Contributes to Gliomagenesis and Differentiation of Glioma Stem Cells.
|
29937714 |
2018 |
Glioma
|
0.900 |
AlteredExpression
|
disease |
BEFREE |
Our results showed that combination treatment modulates the expression of p53 in group co-administered with CAPE and Dasatinib after glioma induction in comparison to the group induced with glioma only.
|
29766825 |
2018 |
Glioma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Previously we have identified oligodendrocyte precursor cell (OPC) as the cell of origin for glioma following the concurrent deletion of p53 and NF1 using a mouse genetic mosaic system that can reveal mutant cells prior to malignancy.
|
29392777 |
2018 |